Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount

Loading...
Loading...
  • Calithera Biosciences Inc CALA priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds of $10 million.
  • Each share of common stock is accompanied by a warrant to purchase one common share at an exercise price of $0.54 per share, which is immediately exercisable and will expire in 18 months, and a warrant to purchase one common share at an exercise price of $0.54 per share, which is immediately exercisable and will expire five years from the date of issuance.
  • The offering is expected to close on April 1.
  • SVB Leerink and H.C. Wainwright & Co. are acting as joint book-running managers for the offering.
  • Related: Why Did Calithera Shares Drop To 52-Week Low In Premarket Friday?
  • Calithera Biosciences will use the proceeds to further the clinical development of mivavotinib, SYK inhibitor, and sapanisertib, dual TORC 1/2 inhibitor, in Phase 2 clinical trials, fund clinical development of additional clinical candidates, and early-stage research.
  • See the offer prospectus here.
  • Price Action: CALA shares are down 31.4% at $0.41 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFinancingOfferingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...